Respiratory Syncytial Virus News and Research

RSS

Ebola research: an interview with Professor Easton, University of Warwick

Ebola virus belongs to a group of viruses that have been known for some time. It was first isolated as a result of an infection in a primate, in a monkey colony, in monkeys that were being used for research in the Philippines.

28 May 2014

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Dr. Richard Plemper, a professor in the new Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.83 million federal grant to develop novel therapeutics against Respiratory Syncytial Virus (RSV) infection.

25 Apr 2014

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences.

22 Apr 2014

Study reports benefits of implementing bronchiolitis guidelines at Children's Medical Center Dallas

Bronchiolitis, the number-one cause of infant hospitalizations nationally, was the focus of a multidisciplinary effort by physicians and clinicians at Children's Medical Center Dallas to establish and implement clinical practice guidelines (CPGs) aimed at streamlining care and reducing unnecessary tests and therapies.

29 Mar 2014

Finding could lead to first effective vaccine against respiratory syncytial virus

Vanderbilt University scientists have contributed to a major finding, reported today in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

9 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

The flu season is in full swing starting mostly in the second week of January when emergency rooms are more busy than usual with patient with flu like symptoms. Dr. James Kojian, E.R. expert and founder of DRTOHELP.COM, warns the public about five things your doctor may be doing wrong when treating for the flu.

25 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

New technique could help researchers unlock the secrets of respiratory syncytial virus

By the time they're two, most children have had respiratory syncytial virus and suffered symptoms no worse than a bad cold. But for some children, especially premature babies and those with underlying health conditions, RSV can lead to pneumonia and bronchitis - which can require hospitalization and have long-term consequences.

30 Dec 2013

Exposure to dust from homes with dogs may alter immune response to allergens

A new study suggests that exposure to dust from homes with dogs may alter the immune response to allergens and other asthma triggers by affecting the composition of the gut microbiome-the community of microbes that naturally colonize the digestive tract.

17 Dec 2013

WSU researchers discover how Nipah virus employs burglary-ring-like teamwork to infiltrate human cell

A team of scientists from Washington State University has discovered how one of the planet's most deadly known viruses employs burglary-ring-like teamwork to infiltrate the human cell.

17 Dec 2013

Research finds reduced allergy risk among children raised with dogs from birth

Children's risk for developing allergies and asthma is reduced when they are exposed in early infancy to a dog in the household, and now researchers have discovered a reason why.

17 Dec 2013

Autumn-born children prone to asthma

Month of birth closely correlates with the prevalence of bronchial asthma, a major study of Taiwanese children has found.

5 Dec 2013

Scientists identify genetic signature of respiratory syncytial virus

Scientists have identified the genetic signature of respiratory syncytial virus, the leading cause of infant hospitalizations around the world. The work is a key step toward a better understanding of the immune response to RSV, which will aid the development of a vaccine and a tool that could allow physicians to determine the severity of the infection when symptoms first develop. The study, from a team at The Research Institute at Nationwide Children's Hospital, was published this week in PLOS Medicine.

15 Nov 2013

Teva Cutting 5,000 Jobs In Global Restructuring

...

10 Oct 2013

Kentucky researcher uses advanced biomedical technology to study HMPV

You may not know the human metapneumovirus by name, but chances are that you have met somewhere before.

22 Aug 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.

18 Jul 2013

International researchers solve three-dimensional structure of respiratory syncytial virus

Young children and the elderly are especially susceptible to respiratory syncytial virus. The three-dimensional structure of respiratory syncytial virus has been solved by an international team from Finland and Switzerland.

18 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

Respiratory Syncytial Virus News and Research

Ebola research: an interview with Professor Easton, University of Warwick

Georgia State researcher receives grant to develop novel therapeutics against RSV infection

Study finds ginseng can help prevent, treat influenza and RSV infection

Study reports benefits of implementing bronchiolitis guidelines at Children's Medical Center Dallas

Finding could lead to first effective vaccine against respiratory syncytial virus

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Researchers design new vaccine for human-infecting respiratory syncytial virus

E.R. expert warns public about 5 things doctor may do wrong when treating for flu

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

New technique could help researchers unlock the secrets of respiratory syncytial virus

Exposure to dust from homes with dogs may alter immune response to allergens

WSU researchers discover how Nipah virus employs burglary-ring-like teamwork to infiltrate human cell

Research finds reduced allergy risk among children raised with dogs from birth

Autumn-born children prone to asthma

Scientists identify genetic signature of respiratory syncytial virus

Teva Cutting 5,000 Jobs In Global Restructuring

Kentucky researcher uses advanced biomedical technology to study HMPV

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

International researchers solve three-dimensional structure of respiratory syncytial virus

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News